Agios Pharmaceuticals Inc. shares fell after the drug developer said it is no longer pursuing a second drug candidate to treat a rare form of anemia. Agios shares dropped 19% to $45.55 after hours. The company said it will no longer develop the AG-519 treatment for pyruvate kinase deficiency, an inherited condition where gene mutations from each parent cause an accelerated destruction of red blood cells, after the Food and Drug Administration put a clinical study of the drug on hold. Agios said the decision does not affect the development of another drug candidate, AG-348, for the condition.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.